Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium

被引:43
作者
Bermudez, LE
Inderlied, CB
Kolonoski, P
Petrofsky, M
Aralar, P
Wu, M
Young, LS
机构
[1] Kuzel Inst Arthrit & Infect Dis, Calif Pacific Med Ctr Res Inst, San Francisco, CA USA
[2] Univ So Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA
关键词
D O I
10.1128/AAC.45.1.217-222.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 mug/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 mug/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 mug/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BL bg(+)/bg(+) mice with 3 x 10(7) MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg/kg/day or 100 mg/kg/day), ethambutol (100 mg/kg/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg/kg/day), azithromycin (200 mg/kg/day), or rifabutin (40 mg/kg/ day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 24 条
[1]   ACTIVITY OF KRM-1648 ALONE OR IN COMBINATION WITH ETHAMBUTOL OR CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM IN BEIGE MOUSE MODEL OF DISSEMINATED INFECTION [J].
BERMUDEZ, LE ;
KOLONOSKI, P ;
YOUNG, LS ;
INDERLIED, CB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) :1844-1848
[2]   Activities of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice [J].
Bermudez, LE ;
Inderlied, CB ;
Kolonoski, P ;
Wu, M ;
BarbaraBurnham, L ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :546-551
[3]   CLARITHROMYCIN, DAPSONE, AND A COMBINATION OF BOTH USED TO TREAT OR PREVENT DISSEMINATED MYCOBACTERIUM-AVIUM INFECTION IN BEIGE MICE [J].
BERMUDEZ, LE ;
INDERLIED, CB ;
KOLONOSKI, P ;
PETROFSKY, M ;
YOUNG, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2717-2721
[4]   Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy [J].
Bermudez, LE ;
Petrofsky, M ;
Kolonoski, P ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :180-183
[5]   Mefloquine is active in vitro and in vivo against Mycobacterium avium complex [J].
Bermudez, LE ;
Kolonoski, P ;
Wu, M ;
Aralar, PA ;
Inderlied, CB ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1870-1874
[6]   CLARITHROMYCIN THERAPY FOR BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE - A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY IN PATIENTS WITH AIDS [J].
CHAISSON, RE ;
BENSON, CA ;
DUBE, MP ;
HEIFETS, LB ;
KORVICK, JA ;
ELKIN, S ;
SMITH, T ;
CRAFT, JC ;
SATTLER, FR ;
STOOL, EW ;
MACGREGOR, RR ;
BUEHNER, T ;
WU, AW ;
BARNES, GL ;
BECKER, R ;
URBANSKI, P ;
RICHARDSON, W ;
HAFNER, R ;
DIXON, D ;
FEIGAL, DW ;
DELLERSON, M ;
GUPTA, S ;
HENRY, D ;
SCHLAGER, S .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (12) :905-911
[7]   PULMONARY INFECTION WITH NONTUBERCULOUS MYCOBACTERIA [J].
CONTRERAS, MA ;
CHEUNG, OT ;
SANDERS, DE ;
GOLDSTEIN, RS .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (01) :149-152
[8]   In vitro activity of Bay 12-8039, a new 8-methoxyquinolone [J].
Fass, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1818-1824
[9]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
[10]   MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
HAWKINS, CC ;
GOLD, JWM ;
WHIMBEY, E ;
KIEHN, TE ;
BRANNON, P ;
CAMMARATA, R ;
BROWN, AE ;
ARMSTRONG, D .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) :184-188